T2	MajorClaim 62 136	there is no standard therapy for patients with advanced gastric carcinoma.
T3	Claim 137 237	The superiority of combination therapy over monochemotherapy has not been demonstrated convincingly.
T4	Premise 1312 1405	The median duration of response was 8.8 and 8.3 months, respectively, in Study A and Study B.
T5	Premise 1406 1478	The median survival reached 8 months in Study A and 9 months in Study B.
T6	Premise 1479 1589	In the whole population of patients survival was significantly higher in patients with a PS of 0-1 (P < 0.05).
T7	Premise 1590 1756	Patients with a PS of 0-1 and a resected tumor had the significantly longest survival both in EEP-L treated patients and in all evaluable patients in the two studies.
T8	Premise 1757 1885	The most frequent World Health Organization Grade 3-4 toxic effects were gastrointestinal in Study A and hematologic in Study B.
T9	Premise 1886 1926	No treatment-related death was observed.
T10	Claim 1927 2069	The efficacy of 5-FU, modulated with 6S-LV, is moderate in patients with advanced gastric carcinoma, similar to cisplatin-containing regimens.
T11	Claim 2070 2236	PS and other prognostic factors could influence the response rate, which does not appear to be a reliable parameter for evaluating the outcome of chemotherapy trials.
R1	Support Arg1:T3 Arg2:T2	
R2	Support Arg1:T9 Arg2:T10	
R3	Support Arg1:T4 Arg2:T10	
R4	Support Arg1:T5 Arg2:T10	
R5	Support Arg1:T6 Arg2:T11	
R6	Support Arg1:T7 Arg2:T11	
R7	Support Arg1:T8 Arg2:T10	
